WNT10A and neoplasm: Ligands of the WNT canonical pathway, such as WNT1 and WNT10A, are associated with tumor progression, poor prognosis, and tumor invasiveness in ccRCC patients (Kruck et al., 2013; Piotrowska et al., 2020) by oncogene activation, such as c-Myc and cyclin D1 (Furge et al., 2007; Karim et al., 2016).